Relay Therapeutics Q2 2022 net loss $76.8M; pipeline progress, new board member

Relay Therapeutics, Inc.

2023-Q2 EPS reported -$1.28 revenue$784,000

Net loss $76.8M ($0.71/share) in Q2 2022 vs $193.4M ($2.10) in Q2 2021; prior year included $134.9M ZebiAI acquisition costs.
Cash $838M as of June 30, 2022, down from $958M at Dec 31, 2021; expected to fund operations into at least 2025.
Appointed Sekar Kathiresan, CEO of Verve Therapeutics, to board of directors.
FDA alignment on single-arm trial for RLY-4008 in FGFR2-fusion CCA; interim data showed 62% confirmed partial response (8/13) at 70 mg QD.
Disclosed new breast cancer programs: selective CDK2 inhibitor, ERα degrader, and RLY-5836; RLY-2608 initial data expected H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.